MX2015014512A - PHARMACEUTICAL COMPOSITION, METHODS FOR TREATMENT AND ITS USES. - Google Patents

PHARMACEUTICAL COMPOSITION, METHODS FOR TREATMENT AND ITS USES.

Info

Publication number
MX2015014512A
MX2015014512A MX2015014512A MX2015014512A MX2015014512A MX 2015014512 A MX2015014512 A MX 2015014512A MX 2015014512 A MX2015014512 A MX 2015014512A MX 2015014512 A MX2015014512 A MX 2015014512A MX 2015014512 A MX2015014512 A MX 2015014512A
Authority
MX
Mexico
Prior art keywords
treating
methods
pharmaceutical composition
patients
type
Prior art date
Application number
MX2015014512A
Other languages
English (en)
Inventor
Hans-Juergen Woerle
Odd-Erik Johansen
Maximilian Von Eynatten
Eric Williams Mayoux
Uli Christian Broedl
David Cherney
Nima Soleymanlou
Bruce A Perkins
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US201361813223P priority Critical
Priority to US201361823045P priority
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Priority to PCT/EP2014/057754 priority patent/WO2014170383A1/en
Publication of MX2015014512A publication Critical patent/MX2015014512A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

La presente invención también se refiere a determinados inhibidores de SGLT-2 para tratar, prevenir, retrasar y/o brindar protección contra la progresión de la enfermedad renal crónica en pacientes, por ejemplo, pacientes con prediabetes, diabetes mellitus tipo 1 o tipo 2.The present invention also relates to certain SGLT-2 inhibitors for treating, preventing, delaying and / or providing protection against the progression of chronic kidney disease in patients, for example, patients with prediabetes, type 1 or type 2 diabetes mellitus.
MX2015014512A 2013-04-18 2014-04-16 PHARMACEUTICAL COMPOSITION, METHODS FOR TREATMENT AND ITS USES. MX2015014512A (es)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US201361813223P true 2013-04-18 2013-04-18
US201361823045P true 2013-05-14 2013-05-14
PCT/EP2014/057754 WO2014170383A1 (en) 2013-04-18 2014-04-16 Pharmaceutical composition, methods for treating and uses thereof

Publications (1)

Publication Number Publication Date
MX2015014512A true MX2015014512A (es) 2016-02-09

Family

ID=50543578

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015014512A MX2015014512A (es) 2013-04-18 2014-04-16 PHARMACEUTICAL COMPOSITION, METHODS FOR TREATMENT AND ITS USES.

Country Status (13)

Country Link
US (6) US20140315832A1 (es)
EP (1) EP2986304A1 (es)
JP (2) JP2016520564A (es)
KR (1) KR20150144781A (es)
CN (1) CN105377266A (es)
AU (2) AU2014255727B2 (es)
CA (1) CA2909728A1 (es)
CL (1) CL2015003022A1 (es)
EA (1) EA033286B1 (es)
HK (1) HK1215378A1 (es)
MX (1) MX2015014512A (es)
PH (1) PH12015502310A1 (es)
WO (1) WO2014170383A1 (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US7772191B2 (en) 2005-05-10 2010-08-10 Boehringer Ingelheim International Gmbh Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int USES OF DPP IV INHIBITORS
CN102838599A (zh) 2006-05-04 2012-12-26 贝林格尔.英格海姆国际有限公司 多晶型
PE20091730A1 (es) 2008-04-03 2009-12-10 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
KR20190016601A (ko) 2008-08-06 2019-02-18 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
PE20120017A1 (es) 2009-02-13 2012-02-12 Boehringer Ingelheim Int PHARMACEUTICAL COMPOSITION INCLUDING A SGLT2 INHIBITOR, OPTIONALLY A DPP-IV INHIBITOR, AN ADDITIONAL ANTIDIABETIC AGENT, AND THEIR USES
SI2486029T1 (sl) 2009-09-30 2015-10-30 Boehringer Ingelheim International Gmbh Methods for the preparation of glucopyranosyl substituted benzyl-benzene derivatives
US10610489B2 (en) 2009-10-02 2020-04-07 Boehringer Ingelheim International Gmbh Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof
KR20120107080A (ko) 2009-11-27 2012-09-28 베링거 인겔하임 인터내셔날 게엠베하 리나글립틴과 같은 ｄｐｐ－ｉｖ 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료
JP6034781B2 (ja) 2010-05-05 2016-11-30 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Combination therapy
AR085689A1 (es) 2011-03-07 2013-10-23 Boehringer Ingelheim Int PHARMACEUTICAL COMPOSITIONS OF METFORMIN, LINAGLIPTINE AND AN SGLT-2 INHIBITOR
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
US9192617B2 (en) 2012-03-20 2015-11-24 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
US20130303462A1 (en) 2012-05-14 2013-11-14 Boehringer Ingelheim International Gmbh Use of a dpp-4 inhibitor in podocytes related disorders and/or nephrotic syndrome
US20140303097A1 (en) 2013-04-05 2014-10-09 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
TR201901110T4 (tr) 2013-04-05 2019-02-21 Boehringer Ingelheim Int Empagliflozinin terapötik kullanımları.
WO2015101916A1 (en) 2013-12-30 2015-07-09 Mylan Laboratories Ltd. Process for the preparation of empagliflozin
US10285973B2 (en) 2014-11-10 2019-05-14 Merck Sharp & Dohme Corp. SGLT-2 inhibitors for treating metabolic disorders in patients with renal impairment or chronic kidney disease
WO2016174155A1 (en) * 2015-04-30 2016-11-03 Boehringer Ingelheim International Gmbh Methods and pharmaceutical compositions comprising a sglt2 inhibitor for treating or improving erectile dysfunction
CN109069525A (zh) * 2016-03-16 2018-12-21 勃林格殷格翰国际有限公司 包含依帕列净的药物组合物及其用途
BR112018072401A2 (pt) 2016-06-10 2019-02-19 Boehringer Ingelheim Int combinações de linagliptina e metformina
WO2018058109A1 (en) * 2016-09-26 2018-03-29 Nusirt Sciences, Inc. Compositions and methods for treating metabolic disorders
CA3039745A1 (en) * 2016-11-10 2018-05-17 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
WO2018096164A1 (en) * 2016-11-28 2018-05-31 Novo Nordisk A/S Insulin degludec for treating diabetes
WO2019244171A1 (en) * 2018-06-20 2019-12-26 Alkem Laboratories Ltd. Stable oral pharmaceutical composition of amorphous empagliflozin and process for preparing thereof
CN109846898A (zh) * 2019-02-01 2019-06-07 同济大学 恩格列净在制备治疗和/或预防心肌梗死的药物中的应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6515117B2 (en) 1999-10-12 2003-02-04 Bristol-Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
PH12000002657B1 (en) 1999-10-12 2006-02-21 Squibb Bristol Myers Co C-aryl glucoside SGLT2 inhibitors
CN103435581B (zh) 2004-03-16 2015-08-19 贝林格尔.英格海姆国际有限公司 吡喃葡萄糖基取代的苯基衍生物、含该化合物的药物、其用途及其制造方法
AR051446A1 (es) 2004-09-23 2007-01-17 Squibb Bristol Myers Co Glucosidos de c-arilo como inhibidores selectivos de transportadores de glucosa (sglt2)
DE602005009745D1 (de) 2004-12-16 2008-10-23 Boehringer Ingelheim Pharma Glucopyranosyl-substituierte benzen-derivate, medikamente mit solchen verbindungen, ihre verwendung und herstellungsverfahren dafür
US7723309B2 (en) 2005-05-03 2010-05-25 Boehringer Ingelheim International Gmbh Crystalline forms of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((R)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments
US7713938B2 (en) * 2005-05-03 2010-05-11 Boehringer Ingelheim International Gmbh Crystalline form of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments
US7772191B2 (en) 2005-05-10 2010-08-10 Boehringer Ingelheim International Gmbh Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein
CA2620566A1 (en) 2005-08-30 2007-03-08 Boehringer Ingelheim International Gmbh Glucopyranosyl-substituted benzyl-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture
CN101238112A (zh) 2005-09-08 2008-08-06 贝林格尔·英格海姆国际有限公司 1-氯-4-(β-D-吡喃葡萄糖-1-基)-2-(4-乙炔基-苄基)-苯的晶形、其制备方法及其用于制备药物中的用途
AR056195A1 (es) 2005-09-15 2007-09-26 Boehringer Ingelheim Int Procedimientos para preparar derivados de (etinil-bencil)-benceno sustituidos de glucopiranosilo y compuestos intermedios de los mismos
US7745414B2 (en) 2006-02-15 2010-06-29 Boehringer Ingelheim International Gmbh Glucopyranosyl-substituted benzonitrile derivatives, pharmaceutical compositions containing such compounds, their use and process for their manufacture
PE20080697A1 (es) 2006-05-03 2008-08-05 Boehringer Ingelheim Int Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmaceuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricacion
US8283326B2 (en) 2006-10-27 2012-10-09 Boehringer Ingelheim International Gmbh Crystalline form of 4-(beta-D-glucopyranos-1-yl)-1-methyl-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments
CA2668623A1 (en) 2006-11-06 2008-05-15 Boehringer Ingelheim International Gmbh Glucopyranosyl-substituted benzyl-benzonitrile derivatives, medicaments containing such compounds, their use and process for their manufacture
WO2008055940A2 (en) 2006-11-09 2008-05-15 Boehringer Ingelheim International Gmbh Combination therapy with sglt-2 inhibitors and their pharmaceutical compositions
PE20090938A1 (es) * 2007-08-16 2009-08-08 Boehringer Ingelheim Int Composicion farmaceutica que comprende un derivado de benceno sustituido con glucopiranosilo
WO2010092126A1 (en) * 2009-02-13 2010-08-19 Boehringer Ingelheim International Gmbh Pharmaceutical composition comprising glucopyranosyl diphenylmethane derivatives, pharmaceutical dosage form thereof, process for their preparation and uses thereof for improved glycemic control in a patient
EP2396005A1 (en) 2009-02-13 2011-12-21 Boehringer Ingelheim International GmbH Sglt-2 inhibitor for treating type 1 diabetes mellitus, type 2 diabete mellitus, impaired glucose tolerance or hyperglycemia
DK2483286T3 (en) 2009-09-30 2016-09-19 Boehringer Ingelheim Int PROCESS FOR THE PREPARATION OF A crystal form of 1-chloro-4- (BETA-D-glucopyranos-1-yl) -2- (4 - ((S) -tetrahydrofuran-3-yloxy) benzyl) benzene
SI2486029T1 (sl) 2009-09-30 2015-10-30 Boehringer Ingelheim International Gmbh Methods for the preparation of glucopyranosyl substituted benzyl-benzene derivatives
US10610489B2 (en) * 2009-10-02 2020-04-07 Boehringer Ingelheim International Gmbh Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof
US20120283169A1 (en) 2010-11-08 2012-11-08 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
US20130035298A1 (en) * 2011-07-08 2013-02-07 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof

Also Published As

Publication number Publication date
JP2018027978A (ja) 2018-02-22
AU2019253791A1 (en) 2019-11-14
CA2909728A1 (en) 2014-10-23
US20190134072A1 (en) 2019-05-09
AU2014255727B2 (en) 2019-07-25
EA201501032A1 (ru) 2016-05-31
JP2016520564A (ja) 2016-07-14
US20140315832A1 (en) 2014-10-23
US20200138844A1 (en) 2020-05-07
US20180169126A1 (en) 2018-06-21
WO2014170383A1 (en) 2014-10-23
JP6574231B2 (ja) 2019-09-11
KR20150144781A (ko) 2015-12-28
US20160038525A1 (en) 2016-02-11
US20170333465A1 (en) 2017-11-23
CL2015003022A1 (es) 2016-06-17
EP2986304A1 (en) 2016-02-24
PH12015502310A1 (en) 2016-02-10
CN105377266A (zh) 2016-03-02
AU2014255727A1 (en) 2015-10-01
HK1215378A1 (zh) 2016-08-26
EA033286B1 (ru) 2019-09-30

Similar Documents

Publication Publication Date Title
PH12016501545A1 (en) Antibody molecules to lag-3 and uses thereof
TN2015000353A1 (en) Newcastle disease viruses and uses thereof
TW201614068A (en) Fucosidase from bacteroides and methods using the same
EP3060251A4 (en) Treatment using bruton's tyrosine kinase inhibitors and immunotherapy
BR112016013969A2 (pt) methods of treating or delaying cancer progression and enhancing immune function, use of an antagonist and a taxane in the manufacture of a medicament, composition and ki
PH12014501738B1 (en) Piperidino-pyrimidine derivatives for the treatment of viral infections
IN2015DN01156A (es)
CL2015002472A1 (es) Como inhibidores de mutant idh-yl-oxazolidin-2-onas 3-pirimidin-4.
PH12015501648A1 (en) 2-aminopyrimidine derivatives for the treatment of viral infections
BR112016004194A8 (pt) compostos úteis como imunomoduladores
BR112015022191A8 (pt) heteroaryl compounds and uses thereof
JP2014240408A5 (es)
BR112015011403A2 (pt) uso de akkermansia para o tratamento de distúrbios metabólicos
BR112015022545A2 (pt) compostos de pirazolo e os usos disso
MX2016001037A (es) INHIBITORS OF TRANSCRIPTION FACTORS AND USES.
KR20160034340A (ko) 타우 발현 조절 조성물
PH12016500862A1 (en) Autotaxin inhibitor compounds
BR112015001838A2 (pt) composições de inibidor de efluxo e métodos de tratamento utilizando o mesmo.
EP3054953A4 (en) Hdac inhibitors, alone or in combination with pi3k inhibitors, for treating non-hodgkin's lymphoma
BR112015026006A8 (pt) composto em combinação com um fármaco imunomodulador imid®, composição farmacêutica que os compreende, uso dos mesmos e kit
PH12018501226A1 (en) Methods for treating huntingtons disease
BR112015003332A2 (pt) composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente
KR20180051626A (ko) Modulator of KRAS expression
WO2014062733A3 (en) Substituted benzene compounds
BR112015031475A2 (pt) composto, composição farmacêutica, método para tratamento de uma doença ou condição, kit, e, uso de composto.